


“...A REAL CAN DO ATTITUDE AND INDEPENDENT NATURE THAT ALLOWED PEOPLE TO THRIVE.”

Doug Williams, *Genesis Research and Development*



NEW ZEALAND DELIVERS NEW THERAPEUTIC AND NUTRITIONAL PRODUCTS

The pharmaceutical industry is being driven by growing demand for new therapies, as populations age and as consumers seek more personalised treatments. Growing awareness of the link between lifestyle and longevity is also driving a convergence between medicine and nutrition – creating new market opportunities for pharmaceutical companies.

New Zealand’s biotechnology industry is perfectly placed to help multinationals deliver

new nutritional and therapeutic products. By partnering with New Zealand companies, universities and research institutions, international investors can position themselves to take advantage of world-changing ideas, creative intellect and high value specialisation.

New Zealand’s biotechnology sector focuses on key industries where our country already excels, such as forestry and agriculture. This has enabled us to develop world-class strengths in niche

fields of human health research, agriculture, forestry and animal research, and in forensic and environmental sciences.

Our biotechnology industry boasts a rich pool of creative and commercially-minded scientists. It offers world-class research and development facilities within a stable, cost-competitive business environment, and is actively supported by the New Zealand government.

NEW ZEALAND DELIVERS COMMERCIAL SUCCESS

New Zealand's biotechnology sector already delivers results to multinationals, venture capitalists and international research institutions.

Swiss company Roche and US-based Genentech have invested in the world-leading intellectual property built up by New Zealand scientists. Roche and Genentech are part of a syndicate of investors in a New Zealand cancer therapy company, with links to Stanford and Auckland universities, that specialises in tumour hypoxia products.

California-based Invitrogen manufactures animal-derived products in New Zealand, recognising the value of our excellent animal health environment. New Zealand has Category One status in Europe and is free of animal diseases such as BSE and scrapie.

Living Cell Technologies leverages off our ability to add value to natural resources by applying biological knowledge. Living Cell's New Zealand research facility develops cell lines from pigs for the treatment of diabetes, Huntington's disease and haemophilia.

GlaxoSmithKline (GSK) benefits from the cost advantages of doing clinical trials in New Zealand. GSK helped establish the Medical Research Institute of New Zealand, and the institute is now involved in global trials of new GSK medicines. Multinationals such as Merck Sharp & Dohme, Ego Pharmaceuticals and Nutricia also make use of New Zealand's state of the art Good Manufacturing Practice (GMP) research and formulation facilities.

Swiss venture capital company inventages is leveraging off New Zealand's growing local venture capital market. inventages has become a cornerstone investor in a dedicated New Zealand biotechnology fund that is supported by the New Zealand Government.

Britain's NuPharm values the cost competitiveness of our biotechnology industry, where research and development costs are generally half those of Europe and the United States. New Zealand has a supportive business environment – for example, research and development is 100% tax deductible – and has an intellectual property regime that protects investment.

New Zealand also has expertise in developing new technologies that can be used to advance biotechnology. For example, the Bioengineering Research Institute develops mathematical models for all aspects of human physiology, from genes to whole organs. It also develops the experimental techniques and instrumentation required to measure cell and tissue properties, and to perform model validation experiments.

SHARE THE SUCCESS

To find out how your business can benefit, contact Investment New Zealand, the investment promotion agency of the New Zealand government. Investment New Zealand is a division of New Zealand Trade and Enterprise, the country's national economic development agency. It understands the biotechnology industry and has extensive networks within it, allowing us to identify and facilitate investment opportunities relevant to you.

Biotechnology Investment Manager

Email: BIO@investmentnz.govt.nz

Web: www.investmentnz.govt.nz

New Zealand Office

23–29 Albert Street, Auckland

PO Box 8680 Symonds Street, Auckland

Phone: (64) 9 366 4768

A DIVISION OF NEW ZEALAND TRADE AND ENTERPRISE

www.nzte.govt.nz

